Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate
- PMID: 2972102
- DOI: 10.1007/BF00263642
Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate
Abstract
The effects of long term GnRH treatment with the biodegradable depot formulation of ICI 118.630 on hormone levels and spermatogenesis were investigated in 18 males with advanced prostate cancer. Plasma levels of FSH, LH, testosterone, DHEA-S and SHBG were monitored at regular intervals. The drug suppressed FSH, LH and testosterone significantly and did not affect DHEA-S and SHBG plasma levels. Tissue specimens for histologic assessment and quantitative analysis of germinal cell types were obtained at secondary orchidectomy in 16 patients immediately following GnRH analogue treatment. Germinal cell maturation was arrested at the spermatogonial stage. In two patients discontinuing treatment histologic assessment of secondary orchidectomy specimens 9 and 10 months after the last GnRH analogue depot injection resulted in germinal cell maturation to late spermatids in part of the tubule cross sections. These results indicate that long term administration of the GnRH analogue fails to produce complete testicular sclerosis and spermatogenic arrest might be reversible.
Similar articles
-
Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.Cancer Res. 1990 Feb 1;50(3):568-74. Cancer Res. 1990. PMID: 2137024
-
Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.Br J Urol. 1990 Apr;65(4):376-8. doi: 10.1111/j.1464-410x.1990.tb14759.x. Br J Urol. 1990. PMID: 2140282
-
[Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].Hinyokika Kiyo. 1987 Jan;33(1):141-50. Hinyokika Kiyo. 1987. PMID: 2953179 Japanese.
-
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.Drugs. 1991 Feb;41(2):254-88. doi: 10.2165/00003495-199141020-00008. Drugs. 1991. PMID: 1709853 Review.
-
[A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].Gan To Kagaku Ryoho. 2002 Sep;29(9):1675-87. Gan To Kagaku Ryoho. 2002. PMID: 12355959 Review. Japanese.
Cited by
-
Fertility preservation options in transgender people: A review.Rev Endocr Metab Disord. 2018 Sep;19(3):231-242. doi: 10.1007/s11154-018-9462-3. Rev Endocr Metab Disord. 2018. PMID: 30219984 Review.
-
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007. Drugs Aging. 1995. PMID: 7613021 Review.
-
Controversies in the management of advanced prostate cancer.Br J Cancer. 1999 Jan;79(1):146-55. doi: 10.1038/sj.bjc.6690024. Br J Cancer. 1999. PMID: 10408706 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous